Patients who are immunocompromised because of malignancy have an increased risk of herpes zoster and herpes zoster-related complications. We aimed to investigate the efficacy and safety of an inactivated varicella zoster virus (VZV) vaccine for herpes zoster prevention in patients with solid tumour or haematological malignancies.
Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial / Mullane, Kathleen M; Morrison, Vicki A; Camacho, Luis H; Arvin, Ann; McNeil, Shelly A; Durrand, Jessie; Campbell, Bernadette; Su, Shu-Chih; Chan, Ivan S F; Parrino, Janie; Kaplan, Susan S; Popmihajlov, Zoran; Annunziato, Paula W, Bosi A. - In: THE LANCET INFECTIOUS DISEASES. - ISSN 1473-3099. - STAMPA. - (2019), pp. 25-35. [10.1016/S1473-3099(19)30310-X]
Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial
Bosi AMembro del Collaboration Group
2019
Abstract
Patients who are immunocompromised because of malignancy have an increased risk of herpes zoster and herpes zoster-related complications. We aimed to investigate the efficacy and safety of an inactivated varicella zoster virus (VZV) vaccine for herpes zoster prevention in patients with solid tumour or haematological malignancies.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
